Objective-We aimed to examine associations of lipoprotein(a) (Lp(a)) concentrations with coronary heart disease (CHD) and determine whether current Lp(a) clinical laboratory cut points identify risk of disease incidence in 4 races/ethnicities of the Multi-Ethnic Study of Atherosclerosis (MESA 
T he American Heart Association/American College of Cardiology task force has recently issued guidelines for assessing 10-year atherosclerotic cardiovascular disease risk. 1 Within these guidelines, it is acknowledged that the risk algorithm for predicting disease remains imperfect, and further research is needed to improve risk evaluation-particularly in areas relating to genetic hyperlipidemias in Hispanic and Asian populations. To address this shortfall, the present study examines whether the lipid carrying particle, lipoprotein(a) (Lp(a)), imposes risk of incident coronary heart disease (CHD) across 4 race/ethnic groups in the Multi-Ethnic Study of Atherosclerosis (MESA).
Lp(a) is a well-studied subspecies of low-density lipoprotein that is recognized as a significant risk factor for CHD, [2] [3] [4] [5] [6] [7] [8] [9] and findings from a Mendelian randomization study suggest that elevated Lp(a) may directly contribute to CHD development. 10 Distinguishing it from other apolipoprotein B-containing lipoproteins, Lp(a) blood concentrations are primarily determined by the apo(a) gene, LPA, 11, 12 and are negligibly affected by lifestyle modifications, such as diet and exercise. 9 As a consequence of this strong genetic influence, race-based disparities in Lp(a) concentrations have been documented. Studies have consistently shown that black individuals have 2-to 3-fold higher Lp(a) levels than whites in numerous casecontrol and prospective studies. 2, 4, 5, 13, 14 Although fewer studies have been conducted in Chinese and Hispanic populations, it has been shown that Chinese have lower Lp(a) levels than whites, 15 whereas inconsistent results have been reported in Hispanics. 5, 16, 17 In addition to the race-based differences in Lp(a), it remains unclear whether elevated Lp(a) levels impose a significant risk of CHD across different races/ethnicities. Indeed, it has been observed that black individuals have a substantially higher median level of Lp(a), but a correspondingly higher incidence of CHD is not observed, 18 which suggests that Lp(a) does not impose the degree of CHD risk in blacks as it does in whites.
This disparity between blacks and whites may necessitate race-specific Lp(a) cut points and re-evaluation of the existing 30 mg/dL cut point used by practitioners and clinical laboratories across the US. Supporting the latter, a recommendation by the 2010 European Atherosclerosis Society Consensus Panel 2 advocates a higher cut point of 50 mg/dL.
Given the discrepancies in the literature and the limited research conducted in Hispanic and Chinese populations, we aimed to examine racial/ethnic differences in (1) Lp(a) mass levels and distribution patterns; (2) associations of Lp(a) with incident CHD; (3) the use of existing 30 or 50 mg/dL cut points in identifying CHD risk in a prospective study of 1323 black, 1677 white, 548 Chinese American, and 1044 Hispanic MESA participants during a median 8.5-year followup period.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
Characteristics of MESA participants across the 4 races/ethnic groups at baseline are shown in Table 1 . The age and sex distributions at baseline are comparable. Blacks had the highest median level of Lp(a) compared with Hispanics, Chinese Americans, or whites. Distributions of Lp(a) in blacks, whites, Chinese Americans, and Hispanics are shown in the Figure. Lp(a) levels in all ethnic groups were right-skewed although the black population showed less skewness. The median levels of Lp(a) for the 4 groups were blacks, 35.1 mg/dL; whites, 13.0 mg/dL; Chinese, 12.9 mg/dL; and Hispanics, 13.1 mg/dL.
Associations between baseline Lp(a) levels and CHD incidence >8.5 years of follow-up are shown in Table 2 Net reclassification index (NRI) scores and c-statistics were assessed to determine whether adding Lp(a) to a baseline risk model would more accurately predict CHD cases and noncases in black, white, Chinese, and Hispanic participants, as well as in the population as a whole. Models treating Lp(a) as a continuous (per 1 log unit increase) or categorical variable (>30 or >50 mg/dL) are presented in Table I in the onlineonly Data Supplement. Significant NRI results were observed where Lp(a) >30 mg/dL in black individuals and the entire subcohort. The significant improvement in reclassification was driven largely by correctly predicting a higher risk in those who had events: 73% or 48 cases in black participants and 42% or 100 cases in the subcohort. Using this cutoff also incorrectly predicted a lower risk in those who did not have events: 55% or 692 noncases in black individuals and 32% or 1394 noncases for the subcohort. In contrast, improvements in c-statistics were observed across all models for the vast majority of races/ethnicities (Table I in To further test which cutoff value more accurately reflects the relationship between Lp(a) and CHD events within each race, log-likelihoods of both Cox regression models were compared. In the entire population (n=4593), increasing the Lp(a) cutoff from 30 to 50 mg/dL resulted in a 2 U increase in log-likelihood. Similarly, changing the cutoff from 30 to 50 mg/dL in whites and Hispanics resulted in an increase of 1.6 and 1.9, respectively. In black participants, the higher 50 mg/ dL cutoff resulted in a decrease of 0.6 compared with the 30 mg/dL cutoff although the difference may not be significant.
Discussion
In this prospective study of 4593 MESA participants, we aimed to determine whether Lp(a) levels associate with CHD incidence in Hispanic, black, white, and Chinese participants during a median study follow-up period of 8.5 years. We found that Lp(a) was associated with higher risk of CHD in all participants; however, after stratifying the population by race/ethnicity, significant association only remained in black and white subgroups. Further analyses using Lp(a) cut points revealed that 50 mg/dL identified higher CHD risk in all races except Chinese Americans, whereas the 30 mg/dL cut point detected a significant risk of CHD in black study participants alone.
Lp(a) Levels Across Race/Ethnicity
It is well-documented that Lp(a) levels are strongly influenced by race/ethnicity. Black individuals have been shown to have 2-to 3-fold higher median Lp(a) levels relative to whites in prospective studies and clinical trials 2,4,5,13,14 -a finding confirmed in this MESA subcohort (median of 35.1 mg/dL in blacks versus 13.0 mg/dL in whites; Table 1 16 observed significantly higher Lp(a) levels in 215 Hispanics than in 309 whites. Similar to the MESA population, the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial was composed of 4 races and reported that Lp(a) levels were highest in blacks (n=853; median, 60 nmol/L), followed by Asians (n=138; median, 38 nmol/L), then Hispanics (n=784; median, 24 nmol/L) and finally whites (n=7746; median, 23 nmol/L). 5 The present analysis supports the JUPITER finding that there are no significant differences in Lp(a) levels between whites and Hispanics. In contrast to JUPITER, we showed no significant differences in Lp(a) levels in Chinese Americans than in white participants; however, it should be recognized that the Asian population in JUPITER was smaller (n=138) than the Chinese American population in this MESA subcohort (n=548), and confirmation is therefore warranted.
Apart from differences in median Lp(a) concentrations, Lp(a) distribution patterns also varied by race (Figure) . Whites, Hispanics, and Chinese populations showed rightskewed distribution patterns, whereas the black population showed a relatively more symmetrical distribution pattern with a right-handed tail. These race-based differences in median Lp(a) concentrations and distribution patterns likely have implications for clinical reference ranges and are discussed further below.
Lp(a) Cutoffs and CHD Risk
Lp(a) has largely been found to be a modest, independent risk factor for CHD and atherothrombotic forms of stroke.
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Despite such evidence, guidelines that define normal and elevated/at risk levels have yet to be established. Clinical laboratories in the United States generally designate elevated levels at ≥30 mg/dL; however, several investigators and the 2010 European Atherosclerosis Society Consensus Panel recommend that 50 mg/dL serve as the clinical Lp(a) cutoff to signify higher risk of disease. 2 Given this controversy, we tested these 2 cut points. Our findings agreed with the latter investigators that 50 mg/dL is an appropriate cut point with an important caveat-30 mg/dL may be a suitable for black individuals given that it detected significant risk of CHD. Although such a recommendation may invite controversy, Lp(a) levels ≥30 mg/dL corresponded to an 87% greater risk of CHD in black study participants (P=0.02), but a significantly higher risk was not observed in the 24.8% of whites or 24.2% of Hispanics with Lp(a) levels (≥30 mg/dL), underscoring the importance of having a clinically meaningful Lp(a) cut point specific for black populations. By comparison, whites and Hispanics only showed a greater risk of CHD at the 50 mg/dL threshold.
Lp(a) in Risk Reclassification
The addition of Lp(a) to CHD risk models has been shown to improve NRI and c-statistics (ie, area under the curve) in previous studies of whites, 19, 20 yet no corresponding research has been conducted in other races. NRI scores are presented for all 4 race groups across all models (Table I in the online-only Data Supplement), but results are most relevant where HRs of Lp(a) and CHD were found to be significant. Significant NRI scores were only observed in black individuals (P=0.05) and for the entire population (P=0.04), where Lp(a) >30 mg/dL. In contrast, modest increases in c-statistics were observed across all races and models except in Hispanic and Chinese participants, where Lp(a) was treated as a continuous variable. These contrasting NRI and c-statistic results, as well as the inability to replicate previous findings in whites, 19, 20 are likely because 
Comparing Lp(a) Cutoff Values Using Log-Likelihood
Log-likelihood functions have previously been used to determine optimal cutoff values 21 and to compare model fit among data sets. Although P values cannot be directly computed in this type of comparison, a 1 U increase in log-likelihood was used as an a priori threshold that is suggestive of the superior cutoff value. Selecting the higher 50 mg/dL in whites and Hispanics resulted in an increase of 1.6 and 1.9 in log-likelihoods, respectively, signifying that the 50 mg/dL cutoff is a better fit than the 30 mg/dL. In Black participants, however, the higher cutoff of 50 mg/dL resulted in a decrease of 0.6 compared with the 30 mg/dL cutoff, suggesting that 30 mg/dL may serve as the superior cutoff in black individuals although the difference may not be significant because it did not breach the 1 U threshold.
Lp(a) in Chinese Americans
Unlike findings in other racial/ethnic groups, no relationship between Lp(a) and CHD was observed in Chinese Americans-in contrast to results from previous studies, albeit in native East Asian populations. [22] [23] [24] Our null results are likely because of multiple factors, but the relatively fewer number of Chinese participants (n=548) and lower incidence of CHD events (n=18; 3.28%) limited our statistical power for this subgroup. The possibility that a higher Lp(a) cut point would identify CHD risk in Chinese individuals should not be discounted, and follow-up studies in larger Chinese American populations are warranted.
Strengths and Limitations
This study provided the first large-scale prospective evaluation of Lp(a) and risk of CHD incidence across 4 major race/ ethnic groups in the United States. Despite the limited number of CHD events in this MESA subcohort, particularly after race-stratification, significant relationships between Lp(a) and CHD risk were observed nonetheless. With respect to Lp(a), its immunochemical measurement has historically been challenging because of the variable size of its apo(a) componenta product of the heterogeneity of kringle IV type 2 repeats within apo(a) among individuals. The current study used an Lp(a) assay with antibodies targeted to the uniform region of apo(a) and included 5 apo(a) calibrators with mixed molecular weights to minimize apo(a) size-dependent biases associated with Lp(a) measurement. 25 In terms of limitations, it should be acknowledged that analyses that included the entire subcohort may have led to an imprecise estimate of the Lp(a)-associated risk of CHD because of racial disparities in triglycerides and blood pressure that may not have been overcome with statistical adjustments. In addition, conflicting results for risk reclassification analyses suggest that further investigation is needed in larger populations to determine which Lp(a) value optimally improves event prediction in individual races. Finally, adjustments were made for multiple confounding variables, but the presence of residual confounders remains possible.
Conclusions
The current study provides evidence that race is an important factor when considering the Lp(a) level that imposes a significant risk of CHD development. Our findings suggest that the 30 mg/dL cutoff for Lp(a) is not appropriate in white and Hispanic individuals, and the higher 50 mg/dL cutoff should be considered. In contrast, the 30 mg/dL cutoff remains suitable in black individuals. Further research is necessary to develop the most clinically useful Lp(a) cutoff values in individual races/ethnicities.
